Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2010

View Archived Issues

Banyu and Merck & Co. claim novel Akt1 inhibitors for cancer therapy

Everolimus effective in patients with metastatic pancreatic neuroendocrine tumors

Synta Pharmaceuticals discloses Hsp90 inhibitors for the treatment of cancer

TRPA1 antagonists described by Janssen for the treatment of pain

Roche describes liver X receptor agonists for the treatment of atherosclerosis

Novartis claims ENaC blockers for the treatment of cystic fibrosis

Oramed completes patient enrollment in pivotal phase IIb trial of ORMD-0801

Orexin receptor antagonists for treating sleep disorders claimed by Actelion

Cobalamin oral insulin shows promise in preclinical trials

Michael J. Fox Foundation awards grant for neuroprotective therapies for PD

Halozyme Therapeutics enters research alliance with BioAtla

Novel hybrid potentiator-corrector molecule for the treatment of CF disclosed

Generation of tumor-targeted nanoparticles for potential clinical use

Sorafenib shows low activity in phase II trial in advanced biliary tract carcinoma

Dal-OUTCOMES trial to evaluate dalcetrapib in acute coronary syndrome

NS3/4A protease inhibitors reported by BMS for HCV infection

Shionogi's Cymbalta approved for depression in Japan

Schering-Plough obtains Japanese approval for Bridion

Wyeth launches BeneFIX for hemophilia B

ImmunoCellular's ICT-107 vaccine specifically targets cancer stem cells

Bharat Biotech initiates phase I clinical trial of HN-VAC H1N1 vaccine

Lexicon's LX-4211 demonstrates improvements in phase II trial in type 2 diabetes

New dosage form of Mitsubishi Tanabe's neuroprotectant Radicut approved

BTG initiates phase IIa study of Pleneva in multiple sclerosis

4SC commences dosing in a first-in-man phase I study of 4SC-203

Mitsubishi Tanabe's Remicade approved for the additional indication of psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...